Michael D. Darcy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael D. Darcy has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
Gary M. Ansel
Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus, USA
4 shared publications- Aaron E. Lottes
Cook Research Incorporated, West Lafayette, IN, USA
3 shared publications - Alik Farber
Boston University Chobanian & Avedisian School of Medicine
3 shared publications - Bonnie J. LaFleur
The University of Arizona Cancer Center, The University of Arizona, Tucson, Arizona, USA
3 shared publications - Deepta Bhattacharya
Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ 85724, USA; BIO5 Institute, University of Arizona, Tucson, AZ 85724, USA; Department of Surgery, University of Arizona College of Medicine, Tucson, AZ 85724, USA
3 shared publications Erin E. O’lEary
Cook Research Incorporated, West Lafayette, IN, USA
3 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in The Annals of Thoracic Surgery
One-Year Outcomes of Endovascular Repair of Zone 0/1 Aortic Arch Lesions With a Thoracic Branched Endoprosthesis
- 12 October 2026
- Published by Elsevier in The Annals of Thoracic Surgery
Open AccessOne-Year Outcomes of Endovascular Repair of Zone 0/1 Aortic Arch Lesions With a Thoracic Branched Endoprosthesis
- Open Access
- 24 February 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (3)
Major Adverse Limb Events and Death After Successful Endovascular Revascularization: BEST-CLI Trial
- 24 February 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (3)
Open AccessMajor Adverse Limb Events and Death After Successful Endovascular Revascularization: BEST-CLI Trial
- 8 January 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (3) , 107963
In Memoriam: Plinio Rossi, 1929–2025
- 8 January 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (3) , 107963
In Memoriam: Plinio Rossi, 1929–2025
- Open Access
Cost-effectiveness of endovascular versus open surgery for chronic limb-threatening ischemia
Background: Revascularization for Chronic Limb-Threatening Ischemia (CLTI) may be performed with an endovascular (Endo) or open surgical (Bypass) approach. Objective: To evaluate the cost-effectiveness of Endo versus Bypass surgery for CLTI using data from the Best Endovascular versus Best Surgical Therapy for Patients with CLTI (BEST-CLI) trial. Methods: We developed an individual-level continuous time Markov model that included health states representing the occurrence of adjudicated clinical events from BEST-CLI. Rates of clinical outcomes and health utilities were derived directly from trial data. Costs came from Medicare insurance claims data and physician fee schedule. We calculated the incremental cost per life years gained, incremental quality-adjusted life years (QALYs) gained, incremental net monetary benefit (INMB) and cost per major events of amputation, revascularization, and myocardial infarction (MI) or stroke avoided over a 5– and 10-year time horizon. Sensitivity analyses were performed using a Monte Carlo simulation. Results: In base case analyses conducted over a 5-year time horizon, the mean per person direct medical costs were $227,341 (95% Credible Interval [CrI]: $173,075, $291,443) for Bypass and $243,614 (95% CrI: $190,112, $305,605) for Endo. The mean survival per person was 3.91 years (95% CrI: 3.78, 4.03) for Bypass and 3.88 years (95% CrI: 3.68, 4.06) for Endo. This resulted in Endo being dominated by Bypass surgery with respect to costs per life year gained. The mean QALYs per person were 2.48 (95% CrI: 1.11, 3.49) for Bypass and 2.54 (95% CrI: 1.39, 3.40) for Endo, resulting in an incremental costs per QALY gained of $263,973/QALY and an INMB of –$10,109 (95% CrI: –$168,908, $157,433) at a $100,000/QALY willingness-to-pay threshold for Endo vs. Bypass. The results over 10 years were consistent with those of the 5-year follow-up. In the Monte Carlo simulation, there was only a 55% chance that Bypass was more cost-effective than Endo. Conclusion: In the base case analysis, Bypass was the preferred strategy with respect to survival and QALYs, at conventional willingness to pay thresholds. There was substantial uncertainty around these estimates in probabilistic sensitivity analysis, justifying future research to identify subgroups for whom each of these approaches may definitively be cost-effective.
Open AccessCost-effectiveness of endovascular versus open surgery for chronic limb-threatening ischemia
Background: Revascularization for Chronic Limb-Threatening Ischemia (CLTI) may be performed with an endovascular (Endo) or open surgical (Bypass) approach. Objective: To evaluate the cost-effectiveness of Endo versus Bypass surgery for CLTI using data from the Best Endovascular versus Best Surgical Therapy for Patients with CLTI (BEST-CLI) trial. Methods: We developed an individual-level continuous time Markov model that included health states representing the occurrence of adjudicated clinical events from BEST-CLI. Rates of clinical outcomes and health utilities were derived directly from trial data. Costs came from Medicare insurance claims data and physician fee schedule. We calculated the incremental cost per life years gained, incremental quality-adjusted life years (QALYs) gained, incremental net monetary benefit (INMB) and cost per major events of amputation, revascularization, and myocardial infarction (MI) or stroke avoided over a 5– and 10-year time horizon. Sensitivity analyses were performed using a Monte Carlo simulation. Results: In base case analyses conducted over a 5-year time horizon, the mean per person direct medical costs were $227,341 (95% Credible Interval [CrI]: $173,075, $291,443) for Bypass and $243,614 (95% CrI: $190,112, $305,605) for Endo. The mean survival per person was 3.91 years (95% CrI: 3.78, 4.03) for Bypass and 3.88 years (95% CrI: 3.68, 4.06) for Endo. This resulted in Endo being dominated by Bypass surgery with respect to costs per life year gained. The mean QALYs per person were 2.48 (95% CrI: 1.11, 3.49) for Bypass and 2.54 (95% CrI: 1.39, 3.40) for Endo, resulting in an incremental costs per QALY gained of $263,973/QALY and an INMB of –$10,109 (95% CrI: –$168,908, $157,433) at a $100,000/QALY willingness-to-pay threshold for Endo vs. Bypass. The results over 10 years were consistent with those of the 5-year follow-up. In the Monte Carlo simulation, there was only a 55% chance that Bypass was more cost-effective than Endo. Conclusion: In the base case analysis, Bypass was the preferred strategy with respect to survival and QALYs, at conventional willingness to pay thresholds. There was substantial uncertainty around these estimates in probabilistic sensitivity analysis, justifying future research to identify subgroups for whom each of these approaches may definitively be cost-effective.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e014833
Age-Related Outcomes After Revascularization for Chronic Limb-Threatening Ischemia: An Analysis of BEST-CLI
BACKGROUND: The impact of age on outcomes after revascularization for chronic limb-threatening ischemia has not been studied in a prospective trial. METHODS: A total of 1780 patients were grouped into age quartiles (≤55 years, 55< age ≤65 years, 65< age ≤75 years, and >75 years) and by type of revascularization (open bypass or endovascular). The primary outcome was major adverse limb events (MALE) or death, and the secondary outcomes were above-ankle amputation, reintervention, and major adverse cardiovascular events. RESULTS: Death and major adverse cardiovascular events were significantly higher in the oldest quartile (>75 years), whereas MALE and above-ankle amputation were highest in the youngest cohort (≤55 years). Younger patients (≤55 years) had the lowest adjusted risk of MALE or all-cause death with open bypass compared with endovascular revascularization. There was no difference in MALE or all-cause death by treatment strategy in patients >75 years of age. CONCLUSIONS: Older age was associated with the highest risks of death and major adverse cardiovascular events and the lowest risks of MALE and above-ankle amputation among patients enrolled in BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Chronic Limb-Threatening Ischemia). Age also had a differential impact by revascularization strategy: youngest patients had the lowest risk of MALE and all-cause death with bypass surgery compared with endovascular revascularization, while there was no difference among those >75 years. These data should be used to facilitate shared decision-making in patients with chronic limb-threatening ischemia. REGISTRATION: URL: https://biolincc.nhlbi.nih.gov/studies/best_cli/ ; Unique identifier: HLB02932424a.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e014833
Age-Related Outcomes After Revascularization for Chronic Limb-Threatening Ischemia: An Analysis of BEST-CLI
BACKGROUND: The impact of age on outcomes after revascularization for chronic limb-threatening ischemia has not been studied in a prospective trial. METHODS: A total of 1780 patients were grouped into age quartiles (≤55 years, 55< age ≤65 years, 65< age ≤75 years, and >75 years) and by type of revascularization (open bypass or endovascular). The primary outcome was major adverse limb events (MALE) or death, and the secondary outcomes were above-ankle amputation, reintervention, and major adverse cardiovascular events. RESULTS: Death and major adverse cardiovascular events were significantly higher in the oldest quartile (>75 years), whereas MALE and above-ankle amputation were highest in the youngest cohort (≤55 years). Younger patients (≤55 years) had the lowest adjusted risk of MALE or all-cause death with open bypass compared with endovascular revascularization. There was no difference in MALE or all-cause death by treatment strategy in patients >75 years of age. CONCLUSIONS: Older age was associated with the highest risks of death and major adverse cardiovascular events and the lowest risks of MALE and above-ankle amputation among patients enrolled in BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Chronic Limb-Threatening Ischemia). Age also had a differential impact by revascularization strategy: youngest patients had the lowest risk of MALE and all-cause death with bypass surgery compared with endovascular revascularization, while there was no difference among those >75 years. These data should be used to facilitate shared decision-making in patients with chronic limb-threatening ischemia. REGISTRATION: URL: https://biolincc.nhlbi.nih.gov/studies/best_cli/ ; Unique identifier: HLB02932424a.
- 25 February 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (6) , 950-959
The Incidence and Consequences of Endovascular Technical Failure in Patients with Chronic Limb-Threatening Ischemia: Results from the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb-Threatening Ischemia (BEST-CLI) Trial
- 25 February 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (6) , 950-959
The Incidence and Consequences of Endovascular Technical Failure in Patients with Chronic Limb-Threatening Ischemia: Results from the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb-Threatening Ischemia (BEST-CLI) Trial
- 3 May 2024
- Published by Springer Nature
- p. 257-263
Abdominal Aortic Aneurysms
- 3 May 2024
- Published by Springer Nature
- p. 249-256
Thoracic and Thoracoabdominal Aortic Aneurysms
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 7 (12) , 834-841
No Evidence That Analgesic Use after COVID-19 Vaccination Negatively Impacts Antibody Responses
Uptake of mRNA vaccines, especially booster immunizations, against COVID-19 has been lower than hoped, perhaps in part due to their reactogenicity. Analgesics might alleviate symptoms associated with vaccination, but they might also impact immune responses. We semiquantitatively measured Ab responses following COVID-19 vaccination in 2354 human participants surveyed about analgesic use after vaccination. Participants who used nonsteroidal anti-inflammatory drugs or acetaminophen after vaccination showed elevated Ab levels against the receptor-binding domain of Spike protein relative to those who did not use analgesics. This pattern was observed for both mRNA-1273 and BNT162b2 and across age groups. Participants who used analgesics more frequently reported fatigue, muscle aches, and headaches than did those who did not use painkillers. Among participants who reported these symptoms, we observed no statistically significant differences in Ab levels irrespective of analgesic use. These data suggest that elevated Ab levels are associated with symptoms and inflammatory processes rather than painkiller use per se. Taken together, we find no evidence that analgesic use reduces Ab responses after COVID-19 vaccination. Recommendation of their use to alleviate symptoms might improve uptake of booster immunizations.
- 1 December 2023
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 7 (12) , 834-841
Open AccessNo Evidence That Analgesic Use after COVID-19 Vaccination Negatively Impacts Antibody Responses
Uptake of mRNA vaccines, especially booster immunizations, against COVID-19 has been lower than hoped, perhaps in part due to their reactogenicity. Analgesics might alleviate symptoms associated with vaccination, but they might also impact immune responses. We semiquantitatively measured Ab responses following COVID-19 vaccination in 2354 human participants surveyed about analgesic use after vaccination. Participants who used nonsteroidal anti-inflammatory drugs or acetaminophen after vaccination showed elevated Ab levels against the receptor-binding domain of Spike protein relative to those who did not use analgesics. This pattern was observed for both mRNA-1273 and BNT162b2 and across age groups. Participants who used analgesics more frequently reported fatigue, muscle aches, and headaches than did those who did not use painkillers. Among participants who reported these symptoms, we observed no statistically significant differences in Ab levels irrespective of analgesic use. These data suggest that elevated Ab levels are associated with symptoms and inflammatory processes rather than painkiller use per se. Taken together, we find no evidence that analgesic use reduces Ab responses after COVID-19 vaccination. Recommendation of their use to alleviate symptoms might improve uptake of booster immunizations.
- 24 November 2023
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (12) , 2080-2084
Implications of IR Being a Primary Specialty on the Professional Organizational Relationship between Interventional and Diagnostic Radiology
- 24 November 2023
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 34 (12) , 2080-2084
Implications of IR Being a Primary Specialty on the Professional Organizational Relationship between Interventional and Diagnostic Radiology